Menu
Recruiting NCT04934007

Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder

No phase Interventional Obsessive-Compulsive Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: rTMS Treatment.
Who it may be relevant to
Registry conditions: Obsessive-Compulsive Disorder. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Randomized Control Trial of Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder

Overview

According to the literature the lateral part of the Orbito Frontal Cortex (lOFC) is a relevant bilateral target for repetitive Trans-cranial Magnetic Stimulation (rTMS) in Obsessive Compulsive Disorder (OCD). Both hemispheres are concerned in terms of target.

Interventions

  • Device rTMS Treatment
    1 Hz rTMS

Primary outcome measures

  • Yale Brown Obsessive Compulsive Scale score [Time frame: baseline and 25 days]
Secondary outcome measures (6)
  • Yale Brown Obsessive Compulsive Scale [Time frame: baseline and 70 days]
  • general assessement functioning (GAF) [Time frame: baseline and 25 days]
  • general assessement functioning (GAF) [Time frame: baseline and 70 days]
  • Clinical Global Impression (CGI) [Time frame: baseline and 25 days]
  • Clinical Global Impression (CGI) [Time frame: baseline and 70 days]
  • Adverse events linked to the rTMS treatment [Time frame: 70 days]

Eligibility criteria

Inclusion criteria

  • Age: Participants will be both males and females, 18-65 years of age included.
  • diagnosis of OCD
  • all the patients must have failed to respond to at least two different pharmacological treatment used for at least 6 weeks
  • Affiliation to a social security system (recipient or assignee),
  • Signed written inform consent form

Exclusion criteria

  • The exclusion criteria are a diagnosis of another psychiatric disorder (except for anxious disorders), a diagnosis of a significant active medical illness, pregnancy or other neurological illness
  • In accordance with the safety criteria for rTMS, patients with a history of seizure or bearing pacemakers, mobile metal implants, implanted medical pumps, or metal clips placed inside the skull will also be excluded
  • The patients won't be allowed to change their medication during the trial. The treatment must be stable at least 3 week before day 0.
  • Female subject who is pregnant, or of child-bearing age, sexually active and not using reliable contraception or who is nursing,
  • Patient under curators
  • Patient hospitalized under duress
  • Patient unable to give his or hers informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

France · 2 centers
  • Sorbonne University, Pitié-Salpêtrière Hospital — Paris
  • Centre Hospitalier Henri Laborit — Poitiers

Identifiers

NCT: NCT04934007 · 2017-A02544-49

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗